Author

Rodion A Oseshnyuk

Observed names: Rodion A. Oseshnyuk, Rodion Oseshnyuk, Родион Осешнюк

Observed institution: Institute of Experimental Medicine

OpenAlex ID: A5041760675

Phase 3 Trial of Coronavir (Favipiravir) in Patients with Mild to Moderate COVID-19

2020 · Tatiana Ruzhentsova, Pavel Chukhliaev, et al. · SSRN Electronic Journal · 25

Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19.

2021 · Tatiana A Ruzhentsova, Rodion A Oseshnyuk, et al. · PubMed · 18

Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial

2023 · Aleksandr V. Kudriavtsev, Anna V. Vakhrusheva, et al. · Vaccines · 14

Efficacy and safety of favipiravir in a complex therapy of mild to moderate COVID-19

2020 · ", Tatiana A. Ruzhentsova, et al. · Infectious diseases News Opinions Training · 11

Эффективность и безопасность применения фавипиравира при COVID-19 легкого и среднетяжелого течения: результаты рандомизированного исследования

2020 · Татьяна Руженцова, Павел Чухляев, et al. · 2

Experience of determination of antitumor drugs concentrations as a method of providing the safety of pharmacotherapy

2018 · Gennadii G Rodionov, Igor I Shantyr’, et al. · Reviews on Clinical Pharmacology and Drug Therapy

Works count: 6

Citation count: 70

H-index: 4

I10-index: 4